Physician profile
Matthew C Pender
NPI 1245229905
$2,433.14
in general payments reported to CMS, 2019-2025
31 companies · $17.82 in 2025
The $17.82 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $669 · 2020: $360 · 2021: $634 · 2022: $296 · 2023: $377 · 2024: $79.39 · 2025: $17.82.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $474.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $474.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $408.17 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $267.56 | 2019-2023 | Farxiga |
| Novo Nordisk INC | $197.99 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $136.69 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $129.92 | 2019-2022 | |
| Astellas Pharma US INC | $113.96 | 2019-2023 | Veozah |
| Amgen INC. | $110.38 | 2019-2023 | Repatha, Otezla |
| Xeris Pharmaceuticals, INC. | $105.11 | 2020-2023 | Gvoke Hypopen |
| Pfizer INC. | $102.74 | 2019-2024 | |
| Abbvie INC. | $99.61 | 2021-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $91.55 | 2020-2021 | |
| Lilly USA, LLC | $88.92 | 2020-2025 | Mounjaro, Zepbound |
| Allergan, INC. | $78.17 | 2020 | |
| Sanofi-Aventis U.S. LLC | $73.50 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $56.66 | 2019-2020 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $54.36 | 2022-2023 | |
| Avanir Pharmaceuticals, INC. | $42.91 | 2019-2022 | |
| Ucb, INC. | $36.65 | 2023 | Nayzilam |
| Abbott Laboratories | $26.23 | 2024 | Freestyle Libre 3 |
| Otsuka America Pharmaceutical, INC. | $23.89 | 2022 | |
| Amarin Pharma, INC. | $23.50 | 2020 | |
| Dexcom, INC. | $23.15 | 2024 | Dexcom G6 Transmitter |
| Kowa Pharmaceuticals America, INC. | $22.57 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $17.83 | 2022 | |
| Sanofi Pasteur INC. | $17.35 | 2019 | |
| Halozyme INC | $16.10 | 2023 | |
| Novartis Pharmaceuticals Corporation | $15.96 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $14.75 | 2021 | |
| Ironshore Pharmaceuticals INC. | $14.29 | 2019 | |
| Sunovion Pharmaceuticals INC. | $13.14 | 2019 | |
| Advanced Oxygen Therapy INC. | $9.53 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Pender listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.